Navigation Links
Four of Molecular Medicine's Thought Leaders will Keynote at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference
Date:11/21/2008

market with reduced chance of adverse events (PRECLINICAL DRUG SAFETY)
  • Generate effective business and diversification strategies to maximize progress with problematic targets and diseases ( EXECUTIVE SUMMIT)
  • Leverage informatics tools and strategies to improve R&D success (IT TRACK)

  • Last year's event had record-setting attendance that brought together 3000 delegates from over 40 countries. For questions about the Molecular Medicine Tri-Conference, call Cambridge Healthtech Institute at 781-972-5400; or visit www.Tri-Conference.com.

    About Cambridge Healthtech Institute

    Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

    Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

    www.chicoporate.com

    Press Inquiries Please Contact:
    Tracey Fielding
    Cambridge Healthtech Institute
    Ph. (781) 972-5429

    ###

    Read the full story at http://www.prweb.c
    '/>"/>

    Source: PRWeb
    Copyright©2008 Vocus, Inc.
    All rights reserved

    Page: 1 2 3 4

    Related medicine news :

    1. A new molecular zip code, and a new drug target for Huntingtons disease
    2. New knock-out gene model provides molecular clues to breast cancer
    3. Molecular probe paints cancer cells in living animals, Stanford researchers find
    4. Story ideas from molecular & cellular proteomics
    5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
    6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
    7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
    8. Molecular profiling can accurately predict survival in colon cancer patients
    9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
    10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
    11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... , ... July 31, 2015 , ... ZH Healthcare announces ... 2015. , What is HITaaS? Health IT as a Service (HITaaS) is a Healthcare ... as a service (SaaS). , HITaaS manages all aspects of infrastructure, ...
    (Date:7/31/2015)... ... July 31, 2015 , ... The Women's Excellence ... for Natural Birth . The Karmanos Center for Natural Birth provides a ... With nurses and caregivers that are trained in holistic birth approaches, patients can ...
    (Date:7/31/2015)... , ... July 31, 2015 , ... Physical therapy for knee osteoarthritis ... patient's quality of life. It keeps the patient from doing what they want or need ... have a hard time using the stairs. The patient's exercise regime may be limited by ...
    (Date:7/31/2015)... ... 2015 , ... EB Medicine, leading publisher of clinical journals, ... to announce that it has partnered with AgileMD to release Pediatric Emergency ... Android smartphones and tablets. , “The April 2015 launch of our flagship ...
    (Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers invites the public ... Oregon August 15th, 2015 from 9am – 12pm. Timber frame raisings are ... the entire community as the culmination of months of effort, planning, fundraising, and dreaming ...
    Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3
    ... Best Care Senior,Services has expanded into the Littleton/Denver, ... Service, and Personal,Response Company, is proud to announce ... Care Senior Services for outstanding care. For over ... of our work -- a,sincere concern for the ...
    ... Blood and Plasma Donor Centers, LENEXA, Kan., ... MEDW ), a provider of ClosedLoop(TM) clinical,systems for ... has,completed the acquisition of substantially all of the ... provider of software products and,services that enable blood ...
    ... Industry Sales Increase as Consumers Put Their Trust in Natural, Effective ... ... Oct. 31 There has been a profound shift in,the thinking ... become increasingly proactive in seeking more natural means to fight,sickness. As ...
    ... machinery in a cell to serve their own needs. According ... to gain access to that machinery. , A common target ... or pRb, which serves to block cell division when potentially ... of the retina, this tumor suppressor protein has since been ...
    ... if drug would have same benefit for Caucasians , , ... cancer with an experimental chemotherapy drug after surgery improved ... , The results of the trial won,t mean much ... S-1, is classified as "investigational" in the United States. ...
    ... The Medicare bidding,program for durable medical equipment will ... unless Congress modifies,the program. This is the key ... today by the American Association for Homecare.,The Association ... care, choice of provider, and access to the ...
    Cached Medicine News:Health News:Announcing Always Best Care Senior Services Expansion Into the Littleton/Denver, Colorado Area 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 3Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:How one virus uses mimicry to replicate successfully 2Health News:Chemo Drug Improves Stomach Cancer Survival for Japanese Patients 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3
    (Date:7/31/2015)...  Semler Scientific, Inc. (Nasdaq: SMLR ), a ... insurers and physician groups, today reported financial results for ... "In the second quarter of 2015, Semler reported ... 54%, quarter over quarter revenue growth of 8%, and ... FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., chief ...
    (Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
    (Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
    Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
    ... , SANTA ... nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, ... core question "Should any vaccines be required for children?" , ... certain vaccinations for children entering public schools. Depending on the ...
    ... ... Walking for People With All Types of Multiple Sclerosis , ... Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, ... to improve walking speed in people with any type of multiple ...
    Cached Medicine Technology:Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 2Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
    ... System is the next generation ... the symptoms of BPH. This ... the prostate while dilating the ... well tolerated by patients and ...
    ... proud to announce the release of the OES ... optics with our most commonly used cystoscopy sheaths ... level. Now you can have one instrument that ... the OES Pro cystoscopes offer a superior channel ...
    ... Defibrillator is a simple "1, 2, ... is compact with a streamline design ... only 13.5 lbs. It rapidly charges ... has full summary pre- & post-event ...
    Incontinence Pessaries...
    Medicine Products: